Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC and Report Second Quarter Financial Results on August 6, 2015

Loading...
Loading...
Aquinox Pharmaceuticals, Inc. ("Aquinox")
AQXP
, a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will provide an update on results from secondary endpoints from its recently completed Phase 2 LEADERSHIP randomized clinical trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Aquinox will also provide a general business update and report second quarter 2015 financial results on Thursday, August 6th, 2015 after close of U.S. financial markets. Aquinox will host a conference call and live webcast on Thursday, August 6th, 2015 at 4:45 PM (ET) / 1:45 PM (PT). Presentation slides will accompany the webcast and will be posted to the Aquinox website following completion of the call. Conference Call and Webcast Details: Date: Thursday, August 6th, 2015 Time: 4:45 PM (ET) / 1:45 PM (PT). Toll-free: (866) 357-7878 International: (315) 625-3088 Conference ID: 96372657 Webcast URL: http://edge.media-server.com/m/p/4b67r6k9 The live webcast may be accessed through the "Events & Presentations" page in the "Investor Relations" section of the company's website at www.aqxpharma.com. The archived webcast will also be available on Aquinox's website approximately two hours after the event and will be available for replay for at least 30 days after the event.
Loading...
Loading...
Posted In: NewsFDAPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...